Detail akcie Savara Rg online

Business Summary: Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Financial Summary: BRIEF: For the three months ended 31 March 2024, Savara Inc revenues was not reported. Net loss increased 93% to $20.3M. Higher net loss reflects Research and development - Balancing val increase of 83% to $15.5M (expense), Selling, general and administrative increase of 70% to $4.7M (expense), Stock-based Compensation in R&D increase from $255K to $1.3M (expense).